ArticleClinical kidney journal2026
Kidney outcomes and prognostic factors in biopsy-proven kidney sarcoidosis: a nationwide multicenter cohort study.
Article in Clinical kidney journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
27 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Renal sarcoidosis is a rare manifestation of systemic sarcoidosis. Evidence guiding management remains limited. We aimed to characterize clinical and histopathological features, renal outcomes, and predictors of recovery and relapse in patients with renal sarcoidosis. Methods: In this retrospective, multicenter observational study across hospitals affiliated with the Spanish Group for the Study of Glomerular Diseases, we included patients with biopsy-confirmed renal sarcoidosis and ≥6 months of follow-up. Primary outcomes were renal recovery (defined as >50% improvement in estimated glomerular filtration rate) and disease relapse (renal or extrarenal). Secondary outcomes included progression to end-stage kidney disease (ESKD) and treatment-related complications. Results: In this study, 60 patients with a mean age of 56.8 years were included. Tubulointerstitial involvement predominated (80%), with granulomatous interstitial nephritis in 56.7%, while 23.3% exhibited glomerular disease. Patients with interstitial-only patterns achieved more frequently renal recovery at 12 months compared with those with glomerular involvement (65.9% vs 20%, Conclusions: Renal sarcoidosis exhibits heterogeneous presentations but substantial potential for renal recovery, particularly in patients with granulomatous interstitial nephritis. These findings may support further investigation of pathology-informed treatment strategies aimed at reducing corticosteroid exposure. Prospective studies are needed to define optimal treatment strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.